ID

16658

Beschreibung

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B; ODM derived from: https://clinicaltrials.gov/show/NCT00095121

Link

https://clinicaltrials.gov/show/NCT00095121

Stichworte

Versionen (1)
  1. 30.07.16 30.07.16 -
Hochgeladen am

30. Juli 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Chronic Hepatitis B NCT00095121

Englisch

Eligibility Chronic Hepatitis B NCT00095121

1 Formulare  
Criteria
Beschreibung

Criteria

positive hbsag >= 6 months prior to randomization and positive hbeag at screening.
Beschreibung

Hepatitis B surface antigen positive | Hepatitis B e antigen positive

Datentyp

boolean

Alias
UMLS CUI [1]
C0149709
UMLS CUI [2]
C0392390
serum hbv dna greater than or equal to 1 x 100,000 copies/ml (pcr assay) at initial or confirmatory screening visit.
Beschreibung

Hepatitis B DNA Measurement | Polymerase Chain Reaction

Datentyp

boolean

Alias
UMLS CUI [1]
C3641250
UMLS CUI [2]
C0032520
serum alt levels greater than or equal to 1.5 x uln at both initial and confirmatory screening visits.
Beschreibung

Alanine aminotransferase measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0201836
compensated liver disease with anticipated survival greater than 12 months and with the following laboratory and clinical parameters within 4 weeks of baseline:
Beschreibung

Compensated liver disease | Continuance of life Anticipated

Datentyp

boolean

Alias
UMLS CUI [1]
C3839044
UMLS CUI [2,1]
C0038952
UMLS CUI [2,2]
C3840775
*prothrombin time less than or equal to 1 second above normal range. *total bilirubin less than 1.3 mg/dl or normal direct bilirubin. *serum albumin greater than 3 g/dl (greater than 30 g/l). *no clinical history of ascites, variceal bleeding, encephalopathy or splenomegaly. *adequate renal function defined as creatinine clearance greater than or equal to 80 ml/min (calculated using schwartz formula).
Beschreibung

Prothrombin time assay | Bilirubin, total measurement | Bilirubin, direct measurement Normal | Serum albumin measurement | Ascites | Bleeding varices | Encephalopathies | Splenomegaly | Renal function | Creatinine clearance measurement Creatinine-based formula (Schwartz)

Datentyp

boolean

Alias
UMLS CUI [1]
C0033707
UMLS CUI [2]
C0201913
UMLS CUI [3,1]
C0201916
UMLS CUI [3,2]
C0205307
UMLS CUI [4]
C0523465
UMLS CUI [5]
C0003962
UMLS CUI [6]
C0333106
UMLS CUI [7]
C0085584
UMLS CUI [8]
C0038002
UMLS CUI [9]
C0232804
UMLS CUI [10,1]
C0373595
UMLS CUI [10,2]
C1980037
key exclusion criteria:
Beschreibung

Exclusion Criteria Main

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
received immunoglobulin, interferon or lamivudine therapy within 6 months prior to initial screening visit.
Beschreibung

Immunoglobulins | Interferons | Lamivudine

Datentyp

boolean

Alias
UMLS CUI [1]
C0021027
UMLS CUI [2]
C0021747
UMLS CUI [3]
C0209738
participated in any investigational trial with any investigational compound within 2 months prior to initial screening.
Beschreibung

Study Subject Participation Status | Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
organ or bone marrow transplant recipients.
Beschreibung

Transplanted organ Recipient | Autologous bone marrow transplant Recipient

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0524930
UMLS CUI [1,2]
C1709854
UMLS CUI [2,1]
C0194037
UMLS CUI [2,2]
C1709854
clinical evidence of decompensated liver disease.
Beschreibung

Decompensated liver disease Evidence Clinical

Datentyp

boolean

Alias
UMLS CUI [1,1]
C4075847
UMLS CUI [1,2]
C0332120
UMLS CUI [1,3]
C0205210
a child-pugh-turcotte score greater than 6.
Beschreibung

Child-Pugh-Turcotte score

Datentyp

boolean

Alias
UMLS CUI [1]
C3854424
inability to comply with study requirements.
Beschreibung

Protocol Compliance Unable

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0525058
UMLS CUI [1,2]
C1299582
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Chronic Hepatitis B NCT00095121

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Hepatitis B surface antigen positive | Hepatitis B e antigen positive
Item
positive hbsag >= 6 months prior to randomization and positive hbeag at screening.
boolean
C0149709 (UMLS CUI [1])
C0392390 (UMLS CUI [2])
Hepatitis B DNA Measurement | Polymerase Chain Reaction
Item
serum hbv dna greater than or equal to 1 x 100,000 copies/ml (pcr assay) at initial or confirmatory screening visit.
boolean
C3641250 (UMLS CUI [1])
C0032520 (UMLS CUI [2])
Alanine aminotransferase measurement
Item
serum alt levels greater than or equal to 1.5 x uln at both initial and confirmatory screening visits.
boolean
C0201836 (UMLS CUI [1])
Compensated liver disease | Continuance of life Anticipated
Item
compensated liver disease with anticipated survival greater than 12 months and with the following laboratory and clinical parameters within 4 weeks of baseline:
boolean
C3839044 (UMLS CUI [1])
C0038952 (UMLS CUI [2,1])
C3840775 (UMLS CUI [2,2])
Prothrombin time assay | Bilirubin, total measurement | Bilirubin, direct measurement Normal | Serum albumin measurement | Ascites | Bleeding varices | Encephalopathies | Splenomegaly | Renal function | Creatinine clearance measurement Creatinine-based formula (Schwartz)
Item
*prothrombin time less than or equal to 1 second above normal range. *total bilirubin less than 1.3 mg/dl or normal direct bilirubin. *serum albumin greater than 3 g/dl (greater than 30 g/l). *no clinical history of ascites, variceal bleeding, encephalopathy or splenomegaly. *adequate renal function defined as creatinine clearance greater than or equal to 80 ml/min (calculated using schwartz formula).
boolean
C0033707 (UMLS CUI [1])
C0201913 (UMLS CUI [2])
C0201916 (UMLS CUI [3,1])
C0205307 (UMLS CUI [3,2])
C0523465 (UMLS CUI [4])
C0003962 (UMLS CUI [5])
C0333106 (UMLS CUI [6])
C0085584 (UMLS CUI [7])
C0038002 (UMLS CUI [8])
C0232804 (UMLS CUI [9])
C0373595 (UMLS CUI [10,1])
C1980037 (UMLS CUI [10,2])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Immunoglobulins | Interferons | Lamivudine
Item
received immunoglobulin, interferon or lamivudine therapy within 6 months prior to initial screening visit.
boolean
C0021027 (UMLS CUI [1])
C0021747 (UMLS CUI [2])
C0209738 (UMLS CUI [3])
Study Subject Participation Status | Investigational New Drugs
Item
participated in any investigational trial with any investigational compound within 2 months prior to initial screening.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Transplanted organ Recipient | Autologous bone marrow transplant Recipient
Item
organ or bone marrow transplant recipients.
boolean
C0524930 (UMLS CUI [1,1])
C1709854 (UMLS CUI [1,2])
C0194037 (UMLS CUI [2,1])
C1709854 (UMLS CUI [2,2])
Decompensated liver disease Evidence Clinical
Item
clinical evidence of decompensated liver disease.
boolean
C4075847 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0205210 (UMLS CUI [1,3])
Child-Pugh-Turcotte score
Item
a child-pugh-turcotte score greater than 6.
boolean
C3854424 (UMLS CUI [1])
Protocol Compliance Unable
Item
inability to comply with study requirements.
boolean
C0525058 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video